
BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week
The pairing of two Bristol Myers Squibb immunotherapies is now permitted for the first-line treatment of two types of gastrointestinal cancers, after regulatory decisions handed out this past week that convert the accelerated approval status of the drug …